静脉铁剂羧基麦芽糖铁治疗后1年心肌铁摄取持续存在尽管铁缺乏复发
在临床实践中,静脉铁剂用于纠正铁缺乏,慢性铁缺乏患者常需重复给药。单次标准剂量羧基麦芽糖铁(1000 mg)后,心肌铁快速摄取并持续增加,且不依赖血浆铁蛋白变化;铁缺乏复发时心肌铁未正常化。重复给药可能导致心肌铁累积。
要点
- 单次标准剂量羧基麦芽糖铁1000 mg后,心肌铁快速摄取并持续增加。
- 心肌铁增加不依赖血浆铁蛋白水平变化。
- 铁缺乏复发不伴随心肌铁正常化,重复给药可能致心肌铁累积。
核心结论
- 单次标准剂量羧基麦芽糖铁后心肌铁摄取持续增加,铁缺乏复发时心肌铁未正常化,重复给药可致心肌铁累积。
研究设计与样本
- 原文未报告研究设计与样本量。
主要发现
- 单次标准剂量羧基麦芽糖铁(1000 mg)后,心肌铁快速摄取,心肌铁含量持续增加。
- 心肌铁含量增加独立于血浆铁蛋白水平变化。
- 铁缺乏复发不伴随心肌铁正常化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In clinical practice, intravenous (IV) iron therapy is used for the correction of iron deficiency. Patients with chronic causes of iron deficiency, for example, women with abnormal uterine bleeding, patients with inflammatory bowel disease often require repeated dosing with IV iron therapy. After a single standard dose of IV iron therapy (1000 mg) with ferric carboxymaltose, there is a rapid intake of iron into the myocardium, resulting in a sustained increase in myocardial iron content. The increase in myocardial iron content is independent of changes in plasma ferritin levels, and the recurrence of iron deficiency is not accompanied by a normalisation of myocardial iron. The most important implication is that repeated dosing with IV iron (ferric carboxymaltose) can result in cumulative build-up of iron in the myocardium.
引用
- Piechnik SK, Polzella P, Shah A, et al. Myocardial iron intake following intravenous iron therapy with ferric carboxymaltose is sustained at 1 year despite recurrence of iron deficiency. Br J Haematol. 2024. PMID: 39562805. doi:10.1111/bjh.19915
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。